NCT00998049 · OUTCOME

Median Number of Days of Apheresis

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant · Source last updated 2015-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: days
Interval / dispersion: Full Range
Time frame: Duration of apheresis (up to 7 days)

Groups in this outcome

Plerixafor

Plerixafor 160mg/kg/dose by IV on days 5-8 Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Plerixafor	39

Reported measurements

Source class 1

Values in days · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Plerixafor	4	Not reported	2	5	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
2
upper Limit
5
value
4

denoms

counts
group Id
OG000
value
39
units
Participants

dispersion Type

Full Range

groups

description
Plerixafor 160mg/kg/dose by IV on days 5-8 Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
id
OG000
title
Plerixafor

param Type

MEDIAN

reporting Status

POSTED

time Frame

Duration of apheresis (up to 7 days)

title

Median Number of Days of Apheresis

type

SECONDARY

unit Of Measure

days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice